References reviewed but not cited

1

Allegra L, Grassi C et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138-148

2

Andrews R, Lynch M. Heliox in the treatment of chronic obstructive pulmonary disease. Emergency Medicine Journal 2004; 21(6): 670-675

3

Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC. Home versus center based activity programs in older adults. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004017.pub2. DOI: 10.1002/14651858:CD004017.pub2

4

Austin M, Wood-Baker R. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3 John Wiley & Sons, Ltd Chichester UK DOI: 10.1002/14651858.CD005534.pub2

5

Austin M, Wood-Baker R,  Oxygen therapy in the pre-hospital setting for people suffering from an acute exacerbation of chronic obstructive pulmonary disease.  The Cochrane Database of Systematic Reviews: Protocols 2005 Issue 4. John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD005534

6

Baselli LM, Oswald MA, Nashelsky JM.  Clinical inquiries. Do beta-blockers worsen respiratory status for patients with COPD?  J Fam Pract 2005 May;54(5): 472-3

7

Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61:869-873

8

Beeh KM, Kornmann O, Beier J, Ksoll, M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respiratory Medicine 2004;98:591-7

9

Booker R. Chronic obstructive pulmonary disease and the NICE guideline. Nurs Stand. 2005 Feb 9-15;19(22): 43-52

10

Bourbeau J. Disease-specific self-management programs in patients with advanced chronic obstructive pulmonary disease: a comprehensive and critical evaluation. Disease Management and Health Outcomes 2003;11(5):311-319

11

Bourdin A, Serre I, Flamme H, Vic P, Neveu D, Aubas P, Godard P, Chanez P. Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004;59:488-493

12

British Thoracic Society Guideline. Intermediate-care: Hospital-at-Home in chronic obstructive pulmonary disease. Thorax 2007;62(3):200-210

13

Brown, CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2001 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002984

14

Brown CD, Fessler HE. Lung volume reduction surgery. COPD 2005;2(3):363-75

15

Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol & fluticasone and formoterol & budesonide in patients with COPD. Respiratory Medicine 2003;97:453-7

16

Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, Centanni S. Onset of action of formoterol/ budesonide in single inhaler vs. formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics 2004;17:121-125

17

Chhabra SK, Vijayan VK, Vasu T. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2006;48(2):97-102

18

Colebourn CL, Barber V, Young JD. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia 2007;62(1):34-42

19

Cooper CB & Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640-4

20

Corrao G et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol. 2005 Jan;58(1):92-7

21

Decramer, Marc and Ferguson, Gary. Clinical Safety of Long-Acting â2-Agonist and Inhaled Corticosteroid Combination Therapy in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease,2006 3:3, 163-171

22

de Torres JP, Casanova C, Hernandez C, Abreu J, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes 2006;4:72

23

Devine EC, Pearcy J. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. Patient Education & Counseling. 1996;29(2):167-78

24

Diahn-Warng Perng,Cheng-Che WU, Kang-Cheng Su, Yu-Chin Lee, Reury-Perng Perng, Chi-Wei Tao. Additive benefits of tiotropium in COPD patients treated with long-acting b2 agonists and corticosteroids. Respirology (2006) 11, 598-602

25

Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M, Epstein SK, Hill NS, Nava S, Soares M-A, D'Empaire G, Alia I, Anzueto A. Noninvasive positive-pressure ventilation for respiratory failure after extubation. The New England Journal of Medicine 2004; 350: 2452-2460

26

Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(3):189-99

27

Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research 2007, 8:45

28

Gan WQ, Man SFP, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulmonary Medicine 2005;5:3 doi:10.1186/1471-2466-5-3

29

Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology. 2005 Jan;10(1):9-17

30

Greenstone M & Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000223. DOI: 10.1002/14651858:CD000223

31

Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist S, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523-32

32

Harris et al. Providing patients with reviews of evidence about COPD treatments: A controlled trial of outcomes. Chronic Respiratory Disease 2006;3:133-140

33

Harris M, Smith B, Veale A. Engaging patients in evidence-based medicine: development of a resource for people with chronic obstructive pulmonary disease. Chronic Illn 2005;1(4):330-6

34

Harvey PA et al. Implementing evidence-based guidelines: inpatient management of chronic obstructive pulmonary disease. Intern Med J. 2005 Mar;35(3):151-5

35

Herland K et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-19

36

Hunninghake DB. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thoracic Soc 2005;2(1):44-9

37

Husereau  D, Shukla V, Boucher M, Mensinkai S, Dales R. Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm Med 2004;4:7

38

International Primary Care Respiratory Group (IPCRG). The use  of long-acting beta2-agonists (LABAs) in asthma. IPCRG position statement following warnings from regulatory authorities including the US FDA. September 2006

39

Jolliet P, Tassaux D, Roeseler J, Burdet L, Broccard A, D'Hoore W, Borst F, Reynaert M, Schaller M-D, Chevrolet J-C. Helium-oxygen versus air-oxygen non-invasive pressure support in decompensated chronic obstructive disease: A prospective multicenter study. Crit Care Med  2003; 31(3): 878-884

40

Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002881. DOI: 10.1002/14651858:CD002881

41

Kahn LS, Fox CH, Olawaiye A, Servoss TJ, McLean-Plunkett E. Facilitating quality improvement in physician management of comorbid chronic disease in an urban minority practice. J Natl Med Assoc. 2007 Apr;99(4):377-83

42

Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006;40(6):1096-104

43

Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from non-invasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med. 2003;138(11):861-70

44

Kida K, Wakabayashi R, Mizuuchi T, Murata A. Screening for suspected chronic obstructive pulmonary disease with an eleven-item pre-interview questionnaire (11-Q). Intern Med 2006;45(21):1201-7

45

Kunisaki KM, Rice KL, Niewoehner DE. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence. Drugs Aging. 2007;24(4):303-24

46

Lusuardi M, De Benedetto F, Paggiaro P, Sanguinetti CM, Brazzola G, Ferri P, Donner CF. A randomized controlled trial of office spirometry in asthma and COPD in standard general practice. Chest 2006;129(4):844-852

47

Machado M-C L, Krishnan JA, Buist SA, Bilderback AL, Fazolo GP, Santarosa MG, Queiroga Jr. F, Vollmer WM. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006;174:524-529

48

Maltais F et al.  A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods.  Can Resp J. 2005 May-Jun;12(4): 193-8

49

Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selected phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2006;40(10):1822-8

50

McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119(4):1190-29

51

McNicholas WT, Calverley PMA, Lee A, Edwards JC on behalf of the Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur Respir J 2004; 23:825-831

52

O'Donnell DE, Hernandez P, Aaron S, Bourbeau J, Marciniuk D, Hodder R, Balter M, Ford G, Gervais A, Goldstein R, Maltais F, Road J, McKay V, Schenkel J. Canadian Thoracic Society COPD Guidelines: Summary of highlights for family doctors. Can Respir J 2003;10(4):183-185

53

Oh H, Seo W. Meta-analysis of the effects of respiratory rehabilitation programmes on exercise capacity in accordance with programme characteristics. J Clin Nurs. 2007 Jan;16(1):3-15

54

Oostenbrink JB et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005 Jan-Feb;8(1):32-46

55

Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73(3):285-95

56

Puhan MA et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax. 2005 May;60(5): 367-75

57

Ram FS et al.  Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005 Feb;99(2):135-44

58

Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW.  Pressurised metered-dose inhalers versus all other hand-held inhaler devices to deliver bronchodilators for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2002 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002170

59

Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pulm Med 2006;12(2):132-9

60

Ranes J and Stoller JK. A review of alpha-1 antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 2005;26(2):154-166

61

Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer J-P, Peel N, Haim M, Bruyere O, Reginster J-Y. Inhaled corticosteroid effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis Int. 2003;14:179-190

62

Ringbaek TJ. Home oxygen therapy in COPD patients. Results from the Danish Oxygen register. Dan Med Bull. 2006;53(3):310-25

63

Rodrigo G, Pollack C, Rodrigo C, Rowe B, Walters EH. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD003571. DOI: 10.1002/14651858.CD003571

64

Rodríguez-Roisin R. COPD exacerbations · 5: Management. Thorax 2006;61;535-544

65

Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y, Burge PS. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Patient Education and Counseling 2002;47(4):311-318

66

Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Randomized Controlled Trials. J Gen Intern Med 2003; 18: 213-221

67

Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006;31(2-3):219-30

68

Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. Am Heart J 1989 Sep;118(3):574-80

69

Schermer TRJ & Quanjer PH. COPD screening in primary care: who is sick? Primary Care Respiratory Journal 2007;16(1):49-53

70

Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005;2(1):81-9

71

Shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. Chest 2004;126(3): 903-914

72

Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003;290(17):2301-2312

73

Smith-Sivertsen T and Rortveit G. Should general practitioners screen smokers for COPD. Scand J Prim Health Care 2004;22:196-201

74

Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126(5): 1645-1655

75

Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/ usual therapy: results of a meta-analysis. Respiratory Research 2006;7:147

76

Strange et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine 2007, 7:10

77

Sutherland E Rand. Inhaled steroids and outcomes in COPD: Progressing beyond FEV1. Chest 2007;131(3):648-649

78

Tierney WM et al. Can computer-generated evidence-based care suggestions enhance evidence-based management of asthma and chronic obstructive pulmonary disease? A randomized, controlled trial. Health Serv Res. 2005 Apr;40(2): 477-97

79

Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73(3):296-305

80

University of York Cochrane Centre for Reviews, Dissemination. Inhaler devices for the management of asthma and COPD. Effective Health Care 2003;8(1):1-12

81

Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTAN study group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005;60(4):301-4

82

Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P, TRISTAN Study Group. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. 2004

83

Wedzicha JA, Seemungal TAR. Inhaled corticosteroids in COPD: a light at the end of the tunnel? Thorax 2005;60:977-978

84

Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS.  Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD002878. DOI: 10.1002/14651858:CD002878)

85

Wilson DH, Tucker G, Frith P, Appleton, S, Ruffin RE, Adams RJ. Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia 1993-2003. MJA 2007;186:408-411

86

Wood-Baker R, Walters J, Walters EH. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med. 2007 Mar;101(3):371-7. Epub 2006 Sep 7

87

Xuan W, Correll P, Ampon R, Williamson M, Marks G. Time trends in hospitalisations and deaths due to COPD and asthma among persons aged 55 and over, 1997-2003. Australian Centre for Asthma Monitoring & Woolcock Institute of Medical Research (Poster)

1

Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006 Mar;61(3):189-95

2

Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991 Aug;31(8):714-8

3

Anker SD, John M Pederson, Raguso C, Cicoira M, Dardai E, Laviano A, Ponikowski P, Schols AM; DGEM (German Society for Nutritional Medicine); Becker HF, Bohm M, Brunkhorst FM, Vogelmeier C; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on enteral nutrition: Cardiology and pulmonology. Clin Nutr 2006;25(2):311-8

4

Arandjus C, Black PN, Poole PJ, Wood Baker R, Steurer-Stey C. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med. 2006 Oct;100(10):1671-81

5

Aronow WS, Van Camp S, Turbow M, Whittaker K, Lurie M. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther 1979 Feb;25(2):149-53

6

Balser E, Neher JO, Safranek S, Taraday J. Clinical inquiries: When are antibiotics indicated for acute COPD exacerbations? J Fam Pract. 2006 Dec;55(12):1079-80

7

Baraldi E, Carraro S. Exercise testing and chronic lung diseases in children. Paediatr Respir Rev 2006;7 Suppl 1:S196-8

8

Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007 Mar;101(3):399-410. Epub 2006 Aug 17

9

Beeh KM, Beier J. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? Clin Exp Allergy 2006;36(2):142-157

10

Bellamy D, Bouchard J, Henrischsen S, Johanssen G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15(1):48-57

11

Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J 2006;27(4):682-8

12

Brubacher JR, Levine B, Hoffman RS. Intestinal pseudo-obstruction (Ogilvie's syndrome) in theophylline overdose. Vet Hum Toxicol 1996 Oct;38(5):368-70

13

Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003 Jun;21(6):1012-6

14

Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007 Mar;12(1):23-36. Epub 2007 Mar 8

15

Calverley PM, Scott S.  Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD. 2006 Dec;3(4):233-42

16

Candy B, Taylor SJ, Ramsay J, Esmond G, Griffiths CJ, Bryar RM. Service implications from a comparison of the evidence on the effectiveness and a survey of provision in England and Wales of COPD specialist nurse services in the community. Int J Nurs Stud. 2007 May;44(4):601-10. Epub 2006 Feb 28

17

Casanova C, Baudet JS, del Valle Velasco M, Martin JM, Aguirre-Jaime A, de Torres JP, Celli BR. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004 Jun;23(6):841-5

18

Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thoracic Soc 2006;3(1):58-65

19

Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2007 Apr 18(2):CD006316

20

Cohen L, Kitzes R, Shnaider H. Multifocal atrial tachycardia responsive to parenteral magnesium. Magnes Res 1988 Dec;1(3-4):239-42

21

Curtis JR, Cook DJ, Sinuff T, White DB, Hill N, Keenan SP, Benditt JO, Kacmarek R, Kirchhoff KT, Levy MM; Society of Critical Care Medicine Palliative Noninvasive Positive VentilationTask Force. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy. Crit Care Med. 2007 Mar;35(3):932-9

22

D'Souza AO, Smith MJ, Miller LJ, Kavookjian J. An appraisal of pharmacoeconomic evidence of maintenance therapy in COPD. Chest 2006;129(6):1693-708

23

Donner CF. Acute exacerbation of chronic bronchitis: need for an evidence-based approach. Pulm Pharmacol Ther. 2006;19 Suppl 1:4-10. Epub 2005 Dec 15

24

Duck A. Cost-effectiveness and efficacy in long-term oxygen therapy. Nurs Times. 2006 Feb 14-20;102(7):46-50

25

Durham L, Hancock HC. Critical care outreach 2: uncovering the underpinning philosophy and knowledge through collaborative reflection. Nurs Crit Care. 2006 Sep-Oct;11(5):248-59

26

Foreman MG, Willsie SK. Health care disparities in critical illness. Clin Chest Med. 2006 Sep;27(3):473-86, vii

27

Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74

28

Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4(3):253-62

29

Giudici MC, Gumpert TJ, Heathman LL. Narrow-complex tachycardia. Am Fam Physician 1994 Mar;49(4):823-34

30

Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006 Dec;28(12):2061-9

31

Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax. 2007 Jun 15; [Epub ahead of print]

32

Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006;28(2):330-8

33

Halbert RJ, Isonaka S. International Primary Care Respiratory Group (IPCRG) Guidelines: integrating diagnostic guidelines for managing chronic respiratory diseases in primary care.  Prim Care Respir J 2006;15(1):13-19

34

Harris M, Smith B, Veale A, Esterman A, Frith P, Selim P. Informed consumers as drivers of evidence based medicine: a trial. X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1205

35

Harris M, Wildgoose D, Veale A, Smith B. Patient mediated interventions to increase adoption of evidence: aids and barriers to an intervention in chronic obstructive pulmonary disease (COPD). X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1206

36

Hasanoglu HC, Yildirim Z, Hasanoglu A, Ozcan C, Gokirmak M, Koksal N, Kalkan S. Effects of ranitidine on pulmonary function tests of patients with chronic obstructive pulmonary disease. Pharmacol Res 2003 Jun;47(6):535-9

37

Hurford WE, Cheifetz IM. Respiratory controversies in the critical care setting. Should heliox be used for mechanically ventilated patients? Respir Care. 2007 May;52(5):582-91; discussion 591-4

38

Jarvis H. Exploring the evidence base of the use of non-invasive ventilation. Br J Nurs. 2006 Jul 27-Aug 9;15(14):756-9

39

Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):147-55

40

Keating RJ, Gersh BJ, Hodge DO, Weivoda PL, Patel PJ, Hammill SC, Shen WK. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 2005 Nov 15;96(10):1420-4

41

Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J. 2007 Aug;30(2):293-306. Epub 2007 Apr 25

42

Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol. 2007 Feb;102(2):412-29; quiz 468

43

Kothari SA, Apiyasawat S, Asad N, Spodick DH. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol 2005 Dec;28(12):561-3

44

Kumar D, Saksena RK. Best evidence topic report. Use of Heliox in the management of acute exacerbation of COPD. Emerg Med J. 2007 Jan;24(1):45-8

45

Kuralay E, Cingoz F, Kilic S, Bolcal C, Gunay C, Demirkilic U, Tatar H. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004 Feb;25(2):224-30

46

Lopez CM, House-Fancher MA. Management of atrial fibrillation in patients with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2005 Mar-Apr;20(2):133-40

47

Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration. 2007;74(4):411-7. Epub 2006 Sep 5

48

Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006;130:640-646

49

MacIntyre NR. Corticosteroid therapy and chronic obstructive pulmonary disease. Respir Care 2006;51(3):289-96

50

McCord JK, Borzak S, Davis T, Gheorghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol 1998 Jan 1;81(1):91-3

51

McCrory DC, Brown C, Gray RN, Goslin RE, Kolimaga JT, MacIntyre NR, Oddone EZ, Matchar DB.  Management of acute exacerbations of chronic obstructive pulmonary disease (Structured Abstract) 2001:256

52

Meyer P, Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 2006 Jul 26;24(31-32):5832-8

53

Mojon P. Oral health and respiratory infection. J Can Dent Assoc 2002;68(6):340-5

54

Mokhlesi B. Clinical implications of gastroesophageal reflux disease and swallowing dysfunction in COPD. Am J Respir Med 2003;2(2):117-21

55

Myers T. The value of care algorithms. Pharmacotherapy. 2006 Sep;26(9 Pt 2):181S-91S; discussion 191S-92S

56

O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61(4):354-61

57

Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc. 2007 May;82(5):575-82

58

Oh H, Seo W. Meta-analysis of the effects of respiratory rehabilitation programmes on exercise capacity in accordance with programme characteristics. J Clin Nurs. 2007 Jan;16(1):3-15

59

Okamoto LJ. Outcomes and humanistic issues related to treatment of acute bronchospasm. Pharmacotherapy. 2006 Sep;26(9 Pt 2):175S-80S

60

Padula CA, Yeaw E. Inspiratory muscle training: integrative review. Res Theory Nurs Pract. 2006 Winter;20(4):291-304

61

Padula CA, Yeaw E. Inspiratory muscle training: integrative review of use in conditions other than COPD.Res Theory Nurs Pract. 2007;21(2):98-118

62

Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care 2006;51(3):277-88

63

Puhan MA, Schunemann HL, Frey M, Bachmann LM. Value of supplemental interventions to enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients: a systematic review (Provisional record). Respiratory Research 2004;5:25

64

Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease.Respir Care. 2007 Jul;52(7):833-51

65

Sanabria A, Valdiviesco E, Gomez G, Echeverry G. Prophylactic antibiotics in chest trauma: a meta-analysis of high-quality studies. World J Surg 2006;30(10):1843-7

66

Schmier JK, Halpern MT, Jones ML. Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidence (Provisional record). Drugs and Aging 2005;22(9):717-719

67

Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest 2001 Dec;120(6):1783-90

68

Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990 Sep;98(3):672-8

69

Shukla VK, Husereau DR, Boucher M, Mensinkai S, Dales R. Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review. (Structured Abstract) 2002:39

70

Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease,chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006 Jan;31(1):58-69

71

Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Petersson S, Postma DS, Szafranski W, Vestbo J. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007 Mar;131(3):682-9

72

Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease--the effect of ongoing, systemic steroid treatment. Vaccine 2006 Feb 27;24(9):1408-12

73

Stoloff S, Samuels S, Kerney D, Brown CP. Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial. MedGenMed. 2006 Mar 29;8(1):86

74

Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006 Dec;3(4):195-202

75

Taylor NF, Dodd KJ, Shields N, Bruder A. Therapeutic exercise in physiotherapy practice is beneficial: a summary of systematic reviews 2002-2005. Aust J Physiother. 2007;53(1):7-16

76

Tinker R, While A. Promoting quality of life for patients with moderate to severe COPD. Br J Community Nursing 2006;11(7):278-84

77

Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. External validity of randomized controlled trials in COPD. Respir Med. 2007 Jun;101(6):1313-20. Epub 2006 Nov 17

78

 Tsai YH, Lee CJ, Lan RS, Lee CH. Multifocal atrial tachycardia as a prognostic indicator in patients with severe chronic obstructive pulmonary disease requiring mechanical ventilation. Changgeng Yi Xue Za Zhi 1991 Sep;14(3):163-7

79

Tukek T, Yildiz P, Akkaya V, Karan MA, Atilgan D, Yilmaz V, Korkut F. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002 Jul;7(3):222-7

80

Ueng KC, Lee SH, Wu DJ, Lin CS, Chang MS, Chen SA. Radiofrequency catheter modification of atrioventricular junction in patients with COPD and medically refractory multifocal atrial tachycardia. Chest 2000 Jan;117(1):52-9

81

Urbano FL, Pasqual RM. Contemporary issues in the care of patients with chronic obstructive pulmonary disease. J Manag Care Pharm 2005;11(5 Suppl A):S2-13; quiz S14-6

82

Uronis HE, McCrory DC, Samsa GP, Currow DC, Abernethy AP. Palliative oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Protocols 2007 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD006429

83

van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006 May 8;166(9):1016-20

84

Wallace LD, Troy KE. Office-based spirometry for early detection of obstructive lung disease. J Am Acad Nurse Pract 2006;18(9):414-21

85

White RD. Prehospital recognition of multifocal atrial tachycardia: association with acute myocardial infarction. Ann Emerg Med 1992 Jun;21(6):753-6

86

Williams MV, Huddleston J, Whitford K, DiFrancesco L, Wilson M. Advances in hospital medicine: a review of key articles from the literature. Med Clin North Am 2002 Jul;86(4):797-823

87

Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med. 2007 Aug;120(8 Suppl 1):S4-13